Why did the FDA initially refuse Moderna's flu shot?
What regulators said and how the pause unfolded
U.S. regulators declined to accept Moderna’s application to license its mRNA influenza vaccine after reviewers concluded the company’s pivotal trial did not meet the agency’s standards for an "adequate and well-controlled" comparison. The agency’s formal stance was that the way Moderna designed and analysed its study left questions about whether the vaccine had been proven to work against the best available standard of care.
The decision exposed disagreements inside the regulator. Senior officials were reported to have overruled some staff reviewers in the course of the refusal, which intensified scrutiny of how approval decisions are being made. The pushback from outside experts and industry critics was immediate: doctors and vaccine makers warned that blocking review could chill innovation and slow delivery of improved flu protections, particularly for older adults who bear the highest flu burden.
After further discussions between the company and regulators, the agency reversed course and agreed to accept Moderna’s application for review. That change leaves the formal scientific review process — including evaluation of trial design, safety data, and how the vaccine performed against comparators — to proceed.
Key near-term implications
- Manufacturers: heightened uncertainty about what trial designs the FDA will deem acceptable for next-generation vaccines.
- Clinicians and patients: a potential delay in access to new vaccine technology for groups at high risk from influenza.
- Public confidence: the dispute highlighted tensions in regulatory decision-making and drew intense public and political attention.
What to watch next
Regulators will now examine the full data package, including the choice of comparator and the consistency of efficacy and safety results. The outcome will help set precedents for how mRNA technology is applied to seasonal vaccines and could influence industry investment and public-health planning ahead of the next flu season.